Publication | Open Access

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

HepatologyMedicineExpansion TrialLiver CancerAdvanced Hepatocellular CarcinomaCancer TreatmentCheckmate 040OncologyRadiation OncologyHepatocellular CarcinomaRadiologyHealth Sciences